Skip to main content
. 2021 Oct;62(10):1430–1437. doi: 10.2967/jnumed.120.259069

FIGURE 6.

FIGURE 6.

(A) Kaplan–Meier curves showing no difference in TTTC in patients with high PSMA-avid tumor burden at baseline (blue curve) and low PSMA-avid tumor burden at baseline (red curve). (B) Patients with lower baseline tumor burden also did not have significantly better OS. Abi/Enza = abiraterone/enzalutamide; HR = hazard ratio.